Molecular interactions between NAFLD and xenobiotic metabolism

Frontiers in Genetics

Volumn 4, Issue JAN, 2013, Pages

  Naik, Adviti ^a   Belič, Aleš ^a   Zanger, Ulrich M ^b,c   Rozman, Damjana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

NAFLD; Nuclear receptors; Phase I and II enzymes; Transporters; Xenobiotic metabolism

Indexed keywords

EID: 84875218268     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00002     Document Type: Review

References (172)

1. Abdelmegeed, M. A., Yoo, S. H., Henderson, L. E., Gonzalez, F. J., Wood-croft, K. J., and Song, B. J. (2011). PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr. 141, 603-610.
2. Alberti, S., Schuster, G., Parini, P., Feltkamp, D., Diczfalusy, U., Rudling, M., et al. (2001). Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXR beta-deficient mice. J. Clin. Invest. 107, 565-573.
3. Aleksunes, L. M., and Klaassen, C. D. (2012). Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-,CAR-,PXR-,PPAR-,and Nrf2-null mice. Drug Metab. Dispos. 40, 1366-1379.
4. Aleksunes, L. M., Slitt, A. L., Maher, J. M., Augustine, L. M., Goedken, M. J., Chan, J. Y., et al. (2008). Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol. 226, 74-83.
5. Alnouti, Y., and Klaassen, C. D. (2008). Regulation of sulfotrans-ferase enzymes by prototypical microsomal enzyme inducers in mice. J. Pharmacol. Exp. Ther. 324, 612-621.
6. Ananthanarayanan, M., Balasubraman-ian, N., Makishima, M., Man-gelsdorf, D. J., and Suchy, F. J. (2001). Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-28865.
7. Anderson, G. W., Zhu, Q. H., Metkowski, J., Stack, M. J., Gopinath, S., and Mariash, C. N. (2009). The Thrsp null mouse (Thrsp(tm1cnm)) and diet-induced obesity. Mol. Cell. Endocrinol. 302, 99-107.
8. Anderson, N., and Borlak, J. (2008). Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60, 311-357.
9. Anstee, Q. M., Daly, A. K., and Day, C. P. (2011). Genetic modifiers of nonalcoholic fatty liver disease progression. Biochim. Biophys. Acta 1812, 1557-1566.
10. Athyros, V. G., Tziomalos, K., Daskalopoulos, G. N., Karagiannis, A., and Mikhailidis, D. P. (2011). Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann. Med. 43, 167-171.
11. Aubert, J., Begriche, K., Knockaert, L., Robin, M. A., and Fromenty, B. (2011). Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin. Res. Hepatol. Gastroenterol. 35, 630-637.
12. Bai, Q., Zhang, X., Xu, L., Kakiyama, G., Heuman, D., Sanyal, A., et al. (2012). Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse mod-elsof nonalcoholic fatty liver disease. Metabolism 61, 836-845.
13. Barbier, O., Duran-Sandoval, D., Pineda-Torra, I., Kosykh, V., Fruchart, J. C., and Staels, B. (2003). Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278, 32852-32860.
14. Barshop,N. J., Capparelli,E.V., Sirlin, C. B., Schwimmer, J. B., and Lavine, J. E. (2011). Acetaminophen pharma-cokinetics in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 52, 198-202.
15. Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., and Bel-lentani, S. (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42, 44-52.
16. Bell, L. N., Molleston, J. P., Morton, M. J., Klipsch, A., Saxena, R., Vup-palanchi, R., et al. (2011). Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J. Clin. Gastroenterol. 45, 800-807.
17. Bell, L. N., Temm, C. J., Saxena, R., Vuppalanchi, R., Schauer, P., Rabi-novitz, M., et al. (2010). Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann. Surg. 251, 1041-1048.
18. Bhalla, S., Ozalp, C., Fang, S., Xiang, L., and Kemper, J. K. (2004). Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactiva-tor PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J. Biol. Chem. 279, 45139-45147.
19. Boergesen, M., Pedersen, T., Gross, B., Van Heeringen, S. J., Hagen-beek, D., Bindesbøll, C., et al. (2012). Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor (in mouse liver reveals extensive sharing of binding sites. Mol. Cell. Biol. 32, 852-867.
20. Breuker, C., Moreau, A., Lakhal, L., Tamasi, V., Parmentier, Y., Meyer, U., et al. (2010). Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). Endocrinology 151, 1653-1661.
21. Browning, J. D., and Horton, J. D. (2004). Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114, 147-152.
22. Browning, J. D., Szczepaniak,L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395.
23. Buechler, C., and Weiss, T. S. (2011). Does hepatic steatosis affect drug metabolizing enzymes in the liver? Curr. Drug Metab. 12, 24-34.
24. Caballero, F., Fernandez, A., De Lacy, A. M., Fernandez-Checa, J. C., Caballe-ria, J., and Garcia-Ruiz, C. (2009). Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 50, 789-796.
25. Calvert, V. S., Collantes, R., Elariny, H., Afendy, A., Baranova, A., Mendoza, M., et al. (2007). A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 46, 166-172.
26. Caro, A. A., and Cederbaum, A. I. (2004). Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 44, 27-42.
27. Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroentero-logical Association. Hepatology 55, 2005-2023.
28. Chen, S., Li, Y., Li, S., and Yu, C. (2008a). A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 23, 1415-1418.
29. Chen, Z. W., Chen, L. Y., Dai, H. L., Chen, J. H., and Fang, L. Z. (2008b). Relationship between ala-nine aminotransferase levels and metabolicsyndromeinnonalcoholic fatty liver disease. J. Zhejiang Univ. Sci. B. 9, 616-622.
30. Chen, Y., and Goldstein, J. A. (2009). The transcriptional regulation of the human CYP2C genes. Curr. Drug Metab. 10, 567-578.
31. Chowdhry, S., Nazmy, M. H., Meakin, P. J., Dinkova-Kostova, A. T., Walsh, S. V., Tsujita, T., et al. (2010). Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic. Biol. Med. 48, 357-371.
32. Cohen, J. C., Horton, J. D., and Hobbs, H. H. (2011). Human fatty liver disease: old questions and new insights. Science 332, 1519-1523.
33. Crespo, J., Cayon, A., Fernandez-Gil, P., Hernandez-Guerra, M., May-orga, M., Dominguez-Diez, A., et al. (2001). Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepa-tology 34, 1158-1163.
34. Dahlman, I., Nilsson, M., Gu, H. F., Lecoeur, C., Efendic, S., Ostenson, C. G., et al. (2009). Functional and genetic analysis in type 2 diabetes of Liver X receptor alleles - a cohort study. BMC Med. Genet. 10:27. doi:10.1186/1471-2350-10-27
35. Day,C.P.(2006). From fat to inflammation. Gastroenterology 130, 207-210.
36. de Alwis, N. M., and Day, C. P. (2008). Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48(Suppl. 1), S104-S112.
37. di Masi, A., De Marinis, E., Ascenzi, P., and Marino, M. (2009). Nuclear receptors CAR and PXR: molecular, functional, and biomed-ical aspects. Mol. Aspects Med. 30, 297-343.
38. Donato, M. T., Jimenez, N., Serralta, A., Mir, J., Castell, J. V., and Gomez-Lechon,M. J. (2007). Effects of steatosis on drug-metabolizing capability of primary human hepa-tocytes. Toxicol. In vitro 21, 271-276.
39. Donato, M. T., Lahoz, A., Jimenez, N., Perez, G., Serralta, A., Mir, J., et al. (2006). Potential impact of steato-sis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos. 34, 1556-1562.
40. Dong, B., Saha, P. K., Huang, W. D., Chen, W. L., Abu-Elheiga, L. A., Wakil, S. J., et al. (2009). Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U.S.A.106, 18831-18836.
41. Dongiovanni, P., Valenti, L., Rametta, R., Daly, A. K., Nobili, V., Mozzi, E., et al. (2010). Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. Gut 59, 267-273.
42. Donnelly,K. L., Smith, C. I., Schwarzen-berg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343-1351.
43. Efanov, A. M., Sewing, S., Bokvist, K., and Gromada, J. (2004). Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53, S75-S78.
44. Elens, L., Becker, M. L., Haufroid, V., Hofman, A., Visser, L. E., Uit-terlinden, A. G., et al. (2011). Novel CYP3A4 intron 6 single nucleotide polymorphism is associ-atedwith simvastatin-mediatedcho-lesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 21, 861-866.
45. Fang, H. L., Strom, S. C., Cai, H., Falany, C. N., Kocarek, T. A., and Runge-Morris, M. (2005). Regulation of human hepatic hydroxys-teroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67, 1257-1267.
46. Faucette, S. R., Sueyoshi, T., Smith, C. M., Negishi, M., Lecluyse, E. L., and Wang, H. (2006). Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not preg-nane X receptor. J. Pharmacol. Exp. Ther. 317, 1200-1209.
47. Feldstein,A. E., Werneburg,N. W., Can-bay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., et al. (2004). Free fatty acids promote hepatic lipo-toxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40, 185-194.
48. Firneisz, G.,Varga, T., Lengyel, G., Feher, J., Ghyczy, D., Wichmann, B., et al. (2010). Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS ONE 5:e12226. doi:10.1371/journal.pone.0012226
49. Fisher, C. D., Lickteig, A. J., Augustine, L. M., Oude Elferink, R. P., Besselsen, D. G., Erickson, R. P., et al. (2009a). Experimental nonalcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol. 613, 119-127.
50. Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., et al. (2009b). Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos. 37, 2087-2094.
51. Fon Tacer, K., and Rozman, D. (2011). Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipids 2011. doi: 10.1155/2011/783976
52. Gao, J., He, J. H., Zhai, Y. G., Wada, T. R., and Xie, W. (2009). The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284, 25984-25992.
53. Gao, J., and Xie, W. (2010). Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab. Dispos. 38, 2091-2095.
54. Gao, J., and Xie, W. (2012). Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol. Sci. 33, 552-558.
55. Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., et al. (2003). Liver perox-isome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276.
56. Gawrieh, S., Baye, T. M., Carless, M., Wallace, J., Komorowski, R., Kleiner, D. E., et al. (2010). Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes. Surg. 20, 1698-1709.
57. Geier, A., Dietrich, C. G., Grote, T., Beuers, U., Prufer, T., Fraunberger, P., et al. (2005). Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43, 1021-1030.
58. Gerbal-Chaloin,S., Daujat, M., Pascussi, J. M., Pichard-Garcia, L., Vilarem, M. J., and Maurel, P. (2002). Tran-scriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277, 209-217.
59. Gerin, I., Dolinsky, V. W., Shackman, J. G., Kennedy, R. T., Chiang, S. H., Burant, C. F., et al. (2005). LXR beta is required for adipocyte growth, glucose homeostasis, and beta cell function. J. Biol. Chem. 280, 23024-23031.
60. Ghose, R., Omoluabi, O., Gandhi, A., Shah, P., Strohacker, K., Carpenter, K. C., et al. (2011). Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 89, 57-64.
61. Gnerre, C., Blättler, S., Kaufmann, M. R., Looser, R., and Meyer, U. A. (2004). Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14, 635-645.
62. Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidore-ductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10, 579-599.
63. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
64. Goodwin, B., Watson, M. A., Kim, H., Miao, J., Kemper, J. K., and Kliewer, S. A. (2003). Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 17, 386-394.
65. Gu, J., Weng, Y., Zhang, Q. Y., Cui, H., Behr, M., Wu, L., et al. (2003). Liver-specific deletion of the NADPH-cytochrome P450 reduc-tase gene: impact on plasma cholesterol homeostasis and the function and regulation of microso-mal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278, 25895-25901.
66. Hafner, M., Rezen, T., and Rozman, D. (2011). Regulation of hepatic cytochromes p450 by lipids and cholesterol. Curr. Drug Metab. 12, 173-185.
67. Handschin, C., and Meyer,U.A. (2005). Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433, 387-396.
68. Hardwick, J. P., Osei-Hyiaman, D., Wiland, H., Abdelmegeed, M. A., and Song, B. J. (2009). PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res. 2009, 952734.
69. Hardwick, R. N., Ferreira, D. W., More, V. R., Lake, A. D., Lu, Z., Manautou, J. E., et al. (2012a). Altered UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. doi:10.1124/dmd.112.048439
70. Hardwick, R. N., Fisher, C. D., Street, S. M., Canet, M. J., and Cher-rington, N. J. (2012b). Molecular mechanism of altered ezetimibe disposition in nonalcoholic steato-hepatitis. Drug Metab. Dispos. 40, 450-460.
71. Hardwick, R. N., Fisher, C. D., Canet, M. J., Lake, A. D., and Cherrington, N. J. (2010). Diversity in antioxi-dant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dis-pos. 38, 2293-2301.
72. Hayes, J. D., Flanagan, J. U., and Jowsey, I. R. (2005). Glutathione trans-ferases. Annu. Rev. Pharmacol. Tox-icol. 45, 51-88.
73. Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., et al. (2012). Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185.
74. Holt, J. A., Luo, G. Z., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K. F., et al. (2003). Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591.
75. Hori, M., Oniki, K., Nakagawa, T., Takata, K., Mihara, S., Marubayashi, T., et al. (2009). Association between combinations of glutathione-S-transferase M1, T1 and P1 genotypes and non-alcoholic fatty liver disease. Liver Int. 29, 164-168.
76. Hori, M., Oniki, K., Ueda, K., Goto, S., Mihara, S., Marubayashi, T., et al. (2007). Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against type 2 diabetes in Japanese. Pharmacogenomics 8, 1307-1314.
77. Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., and Leclercq, I. (2003). Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38, 123-132.
78. Iwasaki, T., Tomeno, W., Yoneda, M., Inamori, M., Shirakawa, J., Imajo, K., et al. (2012). Nonalcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterol-ogy 59, 1522-1525.
79. Jakobsson, T., Treuter, E., Gustafsson, J., and Steffensen, K. R. (2012). Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci. 33, 394-404.
80. Jemnitz, K., Veres, Z., Monostory, K., and Vereczkey, L. (2000). Glu-curonidation of thyroxine in primary monolayer cultures of rat hepatocytes: in vitro induction of UDP-glucuronosyltranferases by methylcholanthrene, clofibrate, and dexamethasone alone and in combination. Drug Metab. Dispos. 28, 34-37.
81. Kallwitz, E. R., McLachlan, A., and Cotler, S. J. (2008). Role of perox-isome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 14, 22-28.
82. Kathirvel, E., Chen, P., Morgan, K., French, S. W., and Morgan, T. R. (2010). Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J. Gastroenterol. Hepatol. 25, 1136-1143.
83. Keber, R., Motaln, H., Wagner, K. D., Debeljak, N., Rassoulzadegan, M., Acimovic, J., et al. (2011). Mouse knockout of the choles-terogenic cytochrome P450 lanos-terol 14alpha-demethylase (Cyp51) resembles Antley-Bixler syndrome. J. Biol. Chem. 286, 29086-29097.
84. Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., and Wahli, W. (1999). Perox-isome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489-1498.
85. Kiba, T., Kintaka, Y., Suzuki, Y., Nakata, E., Ishigaki, Y., and Inoue, S. (2009). Ventromedial hypothalamic lesions change the expression of neuron-related genes and immune-related genes in rat liver. Neurosci. Lett. 455, 14-16.
86. Klein, K., Thomas, M., Winter, S., Nus-sler, A. K., Niemi, M., Schwab, M., et al. (2012). PPARA: a novel genetic determinantof CYP3A4in vitro and in vivo. Clin. Pharmacol. Ther. 91, 1044-1052.
87. Kodama, S., Koike, C., Negishi, M., and Yamamoto, Y. (2004). Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and glu-coneogenic enzymes. Mol. Cell. Biol. 24, 7931-7940.
88. Kolwankar, D., Vuppalanchi, R., Ethell, B., Jones, D. R., Wrightow, S. A., Hall, S. D., et al. (2007). Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin. Gastroenterol. Hepatol. 5, 388-393.
89. Kong, B., Luyendyk, J. P., Tawfik, O., and Guo, G. L. (2009). Farnesoid X receptordeficiency inducesnonalco-holic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328, 116-122.
90. Kumar, R., Rastogi, A., Maras, J. S., and Sarin, S. K. (2012). Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: a favorable endogenous response. Clin. Biochem. 45, 272-274.
91. Kwon do, Y., Jung, Y. S., Kim, S. J., Park, H. K., Park, J. H., and Kim, Y. C. (2009). Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J. Nutr. 139, 63-68.
92. Lake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Bill-heimer, D. D., et al. (2011). Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 1954-1960.
93. Leclercq, I. A., Farrell, G. C., Field, J., Bell, D. R., Gonzalez, F. J., and Robertson, G. R. (2000). CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105, 1067-1075.
94. Lee, J. H., Zhou, J., and Xie, W. (2008). PXR and LXR in hepatic steato-sis: a new dog and an old dog with new tricks. Mol. Pharm. 5, 60-66.
95. Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A., and Cardoso, C. R. (2009). Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29, 113-119.
96. Lewis, J. R., and Mohanty, S. R. (2010). Nonalcoholic fatty liver disease: a review and update. Dig. Dis. Sci. 55, 560-578.
97. Li, J., Huang,J., Li,J. S., Chen,H., Huang, K., and Zheng,L. (2011). Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J. Hepatol. 56, 900-907.
98. Lickteig, A. J., Fisher, C. D., Augustine, L. M., and Cherrington, N. J. (2007). Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohep-atitis. J. Biochem. Mol. Toxicol. 21, 216-220.
99. Lin, Y. C., Chang, P. F., Hu, F. C., Chang, M. H., and Ni, Y. H. (2009). Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 124, e1221-e1227.
100. Lorbek, G., and Rozman, D. (2012). "Cholesterol and inflammation at the crossroads of non-alcoholic fatty liver disease (NAFLD) and atherogenesis," in Atherogenesis, ed. S. Parthasarathy (Rijeka: InTech), 281-304.
101. Machado, M., Marques-Vidal, P., and Cortez-Pinto, H. (2006). Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45, 600-606.
102. Marek, C. J., Tucker, S. J., Konstanti-nou, D. K., Elrick, L. J., Haefner, D., Sigalas, C., et al. (2005). Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387, 601-608.
103. Maroni, L., Guasti, L., Castiglioni, L., Marino, F., Contini, S., Macchi, V., et al. (2011). Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease. Am. J. Med. Sci. 342, 383-387.
104. Martin, I. V., Schmitt, J., Minkenberg, A., Mertens, J. C., Stieger, B., Mull-haupt, B., et al. (2010). Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. Biol. Chem. 391, 1441-1449.
105. Marzolini, C., Tirona, R. G., Gervasini, G., Poonkuzhali, B., Assem, M., Lee, W., et al. (2007). A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21, 1769-1780.
106. Masson, D., Qatanani, M., Sberna, A. L., Xiao, R.,De Barros, J. P. P., Grober, J., et al. (2008). Activationof the constitutive androstane receptor decreases HDL inwild-type and human apoA-I transgenic mice. J. Lipid Res. 49, 1682-1691.
107. Mitsuyoshi, H., Yasui, K., Harano, Y., Endo, M., Tsuji, K., Minami, M., et al. (2009). Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol. Res. 39, 366-373.
108. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., et al. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xeno-biotic and steroid ligands. J. Biol. Chem. 275, 15122-15127.
109. Neuschwander-Tetri, B.A., and Cald-well, S. H. (2003). Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 1202-1219.
110. Nielsen, R., Pedersen, T. A., Hagenbeek, D., Moulos, P., Siersbaek, R., Megens, E., et al. (2008). Genome-wide pro-filingofPPARgamma:RXRandRNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipoge-nesis. Genes Dev. 22, 2953-2967.
111. Osabe, M., Sugatani, J., Fukuyama, T., Ikushiro, S., Ikari, A., and Miwa, M. (2008). Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxi-some proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos. 36, 294-302.
112. Pettinelli, P., and Videla, L. A. (2011). Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J. Clin. Endocrinol. Metab. 96, 1424-1430.
113. Plass, J. R. M., Mol, O., Heegsma, J., Geuken, M.,Faber,K. N.,Jansen,P. L. M., et al. (2002). Farnesoid X receptor and bile salts are involved in tran-scriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35, 589-596.
114. Pokreisz, P., Fleming, I., Kiss, L., Barbosa-Sicard, E., Fisslthaler, B., Falck,J. R.,et al. (2006). Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasocon-striction and pulmonary vascular remodeling. Hypertension 47, 762-770.
115. Pyper, S. R., Viswakarma, N., Yu, S., and Reddy, J. K. (2010). PPARal-pha: energy combustion, hypolipi-demia, inflammation and cancer. Nucl. Recept. Signal. 8, e002.
116. Rakhshandehroo, M., Hooiveld, G., Müller, M., and Kersten, S. (2009). Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS ONE 4:e6796. doi:10.1371/journal.pone.0006796
117. Rakhshandehroo, M., Knoch, B., Muller, M., and Kersten, S. (2010). Peroxi-some proliferator-activated receptor alpha target genes. PPAR Res. 2010. doi: 10.1155/2010/612089
118. Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., et al. (2008). Rosigli-tazone for nonalcoholic steatohep-atitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglita-zone therapy (FLIRT) trial. Gas-troenterology 135, 100-110.
119. Ratziu, V., Voiculescu, M., and Poy-nard, T. (2011). Touching some firm ground in the epidemiology of NASH. J. Hepatol. 56, 23-25.
120. Repa, J. J., Berge, K. E., Pomajzl, C., Richardson, J. A., Hobbs, H., and Mangelsdorf, D. J. (2002). Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277, 18793-18800.
121. Rezen, T. (2011). The impact of cholesterol and its metabolites on drug metabolism. Expert Opin.Drug Metab. Toxicol. 7, 387-398.
122. Rezen, T., Juvan, P., Fon Tacer, K., Kuz-man, D., Roth, A., Pompon, D., et al. (2008). The sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeosta-sis and drug metabolism. BMC Genomics 9:76. doi:10.1186/1471-2164-9-76
123. Rezen, T., Rozman, D., Pascussi, J. M., and Monostory, K. (2011). Interplay between cholesterol and drug metabolism. Biochim. Biophys. Acta 1814, 146-160.
124. Rezen, T., Viola, T., Lovgren-Sandblom, A., Bjorkhem, I., Meyer, U. A., and Rozman, D. (2009). Effect of CAR activation on selected metabolic pathways in normal and hyperlipi-demic mouse livers. BMC Genomics 10:384. doi:10.1186/1471-2164-10-384
125. Richert, L., Lamboley, C., Viollon-Abadie, C., Grass, P., Hartmann, N., Laurent, S., et al. (2003). Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes.Tox-icol. Appl. Pharmacol. 191, 130-146.
126. Rinella,M. E., Elias,M. S., Smolak,R. R., Fu, T., Borensztajn, J., and Green, R. M. (2008). Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J. Lipid Res. 49, 1068-1076.
127. Roberts, E. A. (2007). Pediatric nonalcoholic fatty liver disease (NAFLD): a "growing" problem? J. Hepatol. 46, 1133-1142.
128. Robertson, G., Leclercq, I., and Farrell, G. C. (2001). Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G1135-G1139.
129. Roth, A., Looser, R., Kaufmann, M., and Meyer, U. A. (2008). Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharma-cogenet. Genomics 18, 325-337.
130. Rozman, D., and Monostory, K. (2010). Perspectives of the non-statin hypolipidemic agents. Pharmacol. Ther. 127, 19-40.
131. Runge-Morris, M., and Kocarek, T. A. (2009). Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. PPAR Res. 2009, 728941.
132. Sabol, S. L., Brewer, H. B., and Santamarina-Fojo, S. (2005). The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J. Lipid Res. 46, 2151-2167.
133. Schwartz, K., Lawn,R. M., and Wade, D. P. (2000). ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Bio-phys. Res. Commun. 274, 794-802.
134. Senekeo-Effenberger, K., Chen, S., Brace-Sinnokrak, E., Bonzo, J. A., Yueh, M. F., Argikar, U., et al. (2007). Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxi-some proliferator-activated receptor alpha activation. Drug Metab. Dispos. 35, 419-427.
135. Sirtori, C. R., and Franceschini, G. (1988). Effects of fibrates on serum lipids and atherosclerosis. Pharmacol. Ther. 37, 167-191.
136. Solaas, K., Legry, V., Retterstol, K., Berg, P. R., Holven, K. B., Ferrieres, J., et al. (2010). Suggestive evidence of associations between liver X receptor beta polymorphisms with type 2 diabetes mellitus and obesity inthree cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe). BMC Med. Genet. 11:144. doi:10.1186/1471-2350-11-144
137. Song, X. L., Kaimal, R., Yan, B. F., and Deng, R. T. (2008). Liver receptor homolog 1 transcription-ally regulates human bile salt export pump expression. J. Lipid Res. 49, 973-984.
138. Sookoian, S., Castano, G., Gianotti, T. F., Gemma, C., and Pirola, C. J. (2009). Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 20, 765-770.
139. Sookoian, S., Castano, G. O., Burgueno, A. L., Gianotti, T. F., Rosselli, M. S., and Pirola, C. J. (2010). The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmaco-genet. Genomics 20, 1-8.
140. Stepanova, M., Hossain, N., Afendy, A., Perry, K., Goodman, Z. D., Baranova, A., et al. (2010). Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes. Surg. 20, 640-650.
141. Sueyoshi, T., and Negishi, M. (2001). Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol. 41, 123-143.
142. Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., et al. (2005). Tran-scriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane recep-tor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67, 845-855.
143. Sunny,N. E., Parks,E. J., Browning,J. D., and Burgess, S. C. (2011). Excessive hepatic mitochondrial TCA cycle and gluconeogenesisinhumanswith nonalcoholic fatty liver disease. Cell Metab. 14, 804-810.
144. Tacer, K. F., Kuzman, D., Seliskar, M., Pompon, D., and Rozman, D. (2007). TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol. Genomics 31, 216-227.
145. Takizawa, D., Kakizaki, S., Horiguchi, N., Yamazaki, Y., Tojima, H., and Mori, M. (2011). Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. Carcinogenesis 32, 576-583.
146. Targher, G., Bertolini, L., Padovani, R., Rodella, S., Zoppini, G., Zenari, L., et al. (2006). Relations Between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29, 1325-1330.
147. Tolson, A. H., and Wang, H. B. (2010). Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliv. Rev. 62, 1238-1249.
148. Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., and Evans, R. M. (1998). PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
149. van der Meer, D. L., Degenhardt, T., Väisänen, S., De Groot, P. J., Heinäniemi, M., De Vries, S. C., et al. (2010). Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res. 38, 2839-2850.
150. Varela, N. M., Quinones, L. A., Orel-lana, M., Poniachik, J., Csendes, A., Smok, G., et al. (2008). Study of cytochrome P450 2E1 and its allele variants in liver injury of non-diabetic, nonalcoholic steatohepati-tis obese women. Biol. Res. 41, 81-92.
151. Vernon, G., Baranova, A., and Younossi, Z. M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274-285.
152. Videla, L. A., Rodrigo, R., Orellana, M., Fernandez, V., Tapia, G., Quinones, L., et al. (2004). Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. 106, 261-268.
153. Vollrath, V., Wielandt, A. M., Irure-tagoyena, M., and Chianale, J. (2006). Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem. J. 395, 599-609.
154. Wada, T., Gao, J., and Xie, W. (2009). PXR and CAR in energy metabolism. Trends Endocrinol. Metabol. 20, 273-279.
155. Wagenknecht, L. E., Scherzinger, A. L., Stamm, E. R., Hanley, A. J., Nor-ris, J. M., Chen, Y. D., et al. (2009). Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring) 17, 1240-1246.
156. Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., and Sadee, W. (2011). Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286.
157. Wells, P. G., Mackenzie, P. I., Chowd-hury, J. R., Guillemette, C., Gregory, P. A., Ishii, Y., et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32, 281-290.
158. Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M., and Liddle, C. (1998). Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepa-tology 27, 128-133.
159. Weltman, M. D., Farrell, G. C., and Lid-dle, C. (1996). Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.Gastroente rology 111, 1645-1653.
160. Williams, C. M. (2004). Lipid metabolism in women. Proc. Nutr. Soc. 63, 153-160.
161. Wolbold, R., Klein, K., Burk, O., Nus-sler, A. K., Neuhaus, P., Eichelbaum, M., et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, 978-988.
162. Wree, A., Kahraman, A., Gerken, G., and Canbay, A. (2011). Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 83, 124-133.
163. Wu, K. C., Cui, J. Y., and Klaassen, C. D. (2012). Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. PLoS ONE 7:e39006. doi:10.1371/journal.pone.0039006
164. Xie, W., Radominska-Pandya, A., Shi, Y., Simon, C. M., Nelson, M. C., Ong, E. S., et al. (2001). An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A. 98, 3375-3380.
165. Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., et al. (2007). Inhibiting triglyceride synthesis improves hepatic steato-sis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374.
166. Yamazaki, Y., Kakizaki, S., Horiguchi, N., Sohara, N., Sato, K., Takagi, H., et al. (2007). The role of the nuclear receptor constitutive androstane receptor in the patho-genesis of non-alcoholic steatohep-atitis. Gut 56, 565-574.
167. Younossi, Z. M., Baranova, A., Ziegler, K., Del Giacco,L.,Schlauch, K., Born, T. L., et al. (2005). A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42, 665-674.
168. Zhang, B., Xie, W., and Krasowski, M. D. (2008). PXR: a xenobi-otic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9, 1695-1709.
169. Zheng,H.,Li,S.,Ma,L.,Cheng,L.,Deng, C., Chen, Z., et al. (2011). A novel agonist of PPAR-gamma based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Eur. J. Pharmacol. 659, 244-251.
170. Zhou, C., Tabb, M. M., Nelson, E. L., Grun, F., Verma, S., Sada-trafiei, A., et al. (2006a). Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116, 2280-2289.
171. Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., et al. (2006b). A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 281, 15013-15020.
172. Zhou, K., Donnelly, L., Burch, L., Tavendale, R., Doney, A. S., Leese, G., et al. (2010). Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87, 52-56.